<DOC>
	<DOCNO>NCT01691300</DOCNO>
	<brief_summary>Positron emission tomography combine compute tomography use carbon-11 acetate ( ACT PET/CT ) may help detect lesion treatment evaluate response follow therapy patient multiple myeloma ( MM ) . This study aim prospectively assess clinical utility ACT PET/CT MM compare commonly use F18-fluorodeoxyglucose ( FDG ) .</brief_summary>
	<brief_title>C11-Acetate PET/CT Multiple Myeloma : Added Value F18-Fluorodeoxyglucose PET/CT</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>least 20 year age previously untreated complete pretreatment clinical stag include bone marrow examination write informed consent participate study concurrent active malignant tumor ( ) pregnant breast feeding woman noncompliant PET/CT MRI mark renal impairment ( contraindicate contrastenhanced MRI )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>C11-acetate PET/CT</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Pretreatment stag</keyword>
	<keyword>Response assessment</keyword>
</DOC>